Accéder au contenu
Merck

Discovery of a Novel DNA Gyrase-Targeting Antibiotic through the Chemical Perturbation of Streptomyces venezuelae Sporulation.

Cell chemical biology (2019-07-08)
Scott McAuley, Alan Huynh, Alison Howells, Chris Walpole, Anthony Maxwell, Justin R Nodwell
RÉSUMÉ

Common approaches to antibiotic discovery include small-molecule screens for growth inhibition in target pathogens and screens for inhibitors of purified enzymes. These approaches have a shared intent of seeking to directly target a vital Achilles heel in a pathogen of interest. Here, we report the first screen against a sporulation pathway in a non-pathogenic bacterium as a means of discovering novel antibiotics-this effort has resulted in two important discoveries. First, we show that the sporulation program of Streptomyces venezuelae is exquisitely sensitive to numerous forms of DNA damage. Second, we have identified a DNA gyrase inhibitor. This molecule, EN-7, is active against pathogenic species that are resistant to ciprofloxacin and other clinically important antibiotics. We suggest that this strategy could be applied to other morphogenetic pathways in prokaryotes or eukaryotes as a means of identifying novel chemical matter having scientific and clinical utility.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chloramphénicol, ≥98% (HPLC)
Sigma-Aldrich
Rifampicine, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Vancomycine hydrochloride from Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Mitomycine C from Streptomyces caespitosus, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Carbonylcyanure 3-chlorophénylhydrazone, ≥97% (TLC), powder
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Sigma-Aldrich
Kanamycin B sulfate salt, aminoglycoside antibiotic
Bleomycin sulfate, European Pharmacopoeia (EP) Reference Standard